Back to Search
Start Over
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or METamplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
- Source :
- The Lancet Respiratory Medicine; November 2020, Vol. 8 Issue: 11 p1132-1143, 12p
- Publication Year :
- 2020
-
Abstract
- We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or METamplification having acquired resistance to EGFR inhibition.
Details
- Language :
- English
- ISSN :
- 22132600 and 22132619
- Volume :
- 8
- Issue :
- 11
- Database :
- Supplemental Index
- Journal :
- The Lancet Respiratory Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs53355083
- Full Text :
- https://doi.org/10.1016/S2213-2600(20)30154-5